000 05702cam a2200445Ii 4500
001 96613
003 ES-MaUEC
005 20230102112802.0
006 m o d
007 cr cnu|||unuuu
008 171017s2017 sz ob 000 0 eng d
020 _a331940234X
020 _a3319402366
_q(electronic bk.)
020 _a9783319402345
020 _a9783319402369
_q(electronic bk.)
020 _z9783319402345
_q(print)
040 _aN$T
_beng
_erda
_epn
_cN$T
_dGW5XE
_dN$T
_dOCLCF
_dUAB
_dEBLCP
_dAZU
_dUPM
_dIOG
_dCOO
_dOCLCQ
_dVT2
_dES-MaUEC
_bspa
050 4 _aRC669
_b2017 EB
245 0 0 _aManual of cardio-oncology :
_bcardiovascular care in the cancer patient
_cChiara Lestuzzi, Stefano Oliva, Francesco Ferraù, editors.
264 1 _aCham, Switzerland
_bSpringer International Publishing
_c2017
300 _a1 recurso en línea
336 _aTexto
_btxt
_2rdacontent
337 _aelectrónico
_bc
_2rdamedia
338 _arecurso electrónico
_bcr
_2rdacarrier
347 _atext file
_bPDF
504 _aIncluye referencias bibliográficas
505 0 _a""Foreword""; ""Contents""; ""List of Contributors""; ""I: Introductory Aspects""; ""1: Epidemiology of Cancer: Prevalence, Incidence of Neoplastic Diseases and Trends in Survival in Europe""; ""1.1 Background""; ""1.2 Cancer Distribution""; ""1.2.1 Incidence of All Cancers Excluding Nonmelanoma Skin Cancers""; ""1.2.2 Mortality of All Cancers Excluding Nonmelanoma Skin Cancers""; ""1.3 Lung Cancer""; ""1.3.1 Incidence""; ""1.3.2 Mortality""; ""1.3.3 Risk Factors""; ""1.3.4 Survival""; ""1.4 Breast Cancer""; ""1.4.1 Incidence""; ""1.4.2 Mortality""
505 8 _a""1.4.3 Risk Factors""""1.4.4 Survival""; ""1.5 Colorectal Cancer""; ""1.5.1 Incidence""; ""1.5.2 Mortality""; ""1.5.3 Risk Factors""; ""1.5.4 Survival""; ""1.6 Prostate Cancer""; ""1.6.1 Incidence""; ""1.6.2 Mortality""; ""1.6.3 Risk Factors""; ""1.6.4 Survival""; ""1.7 Discussion""; ""1.8 European Code Against Cancer""; ""References""; ""2: Cancer, Heart Diseases, and Common Risk Factors: Smoke""; ""2.1 Key Points""; ""2.2 Epidemiology""; ""2.3 Cigarette Smoke: Chemicalâ#x80;#x93;Physical Characteristics""; ""2.4 Pathophysiology""
505 8 _a""2.5 Smoke as Risk Factor for Cancer and Other Diseases""""2.6 Conclusions""; ""References""; ""3: Cancer, Heart Diseases and Common Risk Factors: Diet and Physical Activity""; ""3.1 Background""; ""3.2 Diet""; ""3.2.1 Dietary Supplements""; ""3.2.2 Prevention of Cardiotoxicity""; ""3.2.3 Traditional and Alternative Dietary Patterns (. Table 3.1)""; ""3.3 Physical Activity""; ""3.3.1 Physical Activity and Cardiovascular Diseases""; ""3.3.2 Physical Activity in Cancer Prevention (. Fig.  3.5)""; ""3.3.3 Physical Activity After Cancer Diagnosis""
505 8 _a""3.3.4 Cardiovascular Disease, Cancer, and Physical Activity""""References""; ""II: Cardiac Problems as a Consequence of Cancer""; ""4: Thromboembolic Disorders as a Consequence of Cancer""; ""4.1 Introduction""; ""4.2 Clinical Aspects""; ""4.3 Screening for Occult Cancer in Patients with Idiopathic VTE""; ""4.4 Primary Thromboprophylaxis and Identification of High-Risk Outpatients""; ""4.4.1 Surgical Prophylaxis""; ""4.4.2 High-Risk Cancer Outpatients Identification for Primary Thromboprophylaxis""; ""4.4.3 Multiple Myeloma""
505 8 _a""4.5 Appropriate Immediate and Long-Term Treatment for Patients with Acute Thromboembolism and the Role of NOACs""""4.5.1 Acute Treatment (First 10 Days)""; ""4.5.2 Long-Term (First 3 Months) and Extended Therapy (No Planned Stop Date)""; ""4.5.3 Treatment of Catheter-Related DVT""; ""4.5.4 Vena Cava Filters""; ""4.6 Management of Recurrent VTE on Anticoagulation Therapy [55, 63â#x80;#x93;67]""; ""4.7 Treatment Strategy in Patients with Thrombocytopenia""; ""References""; "" Suggested Reading: Society Guidelines""
520 3 _aThis concise and handy manual provides straightforward, up-to-date guidance for cardiologists and other practitioners on the management of cancer patients with cardiac problems, whether they be due to the cancer itself or to antineoplastic treatment. Detailed attention is devoted to the various forms of cardiotoxicity associated with chemotherapy and radiotherapy. The drugs commonly responsible for each toxicity are identified and clear advice is offered on monitoring techniques and treatment approaches. In addition, the issue of cardiotoxicity due to cancer treatment in particular patient groups - children, the elderly, and those with pre-existing cardiac disease - is addressed separately, with guidance on when and how antineoplastic (and/or cardiological) treatments should be modified. Further sections describe the correct responses to cardiac problems secondary to the cancer itself, including thromboembolic disorders and electrolyte imbalances, and the diagnosis, treatment, and follow-up of cardiac tumors. A closing section considers how to improve cooperation between oncologists, cardiologists, and general practitioners to ensure that cancer patients' cardiovascular needs are met in a multidisciplinary approach.
650 7 _aCancer
_xComplications.
_2fast
_0(OCoLC)fst00845337
_9139308
_0comprobar BNE19900970859
700 1 _aFerraù, Francesco,
_eeditor literario
700 1 _aLestuzzi, Chiara,
_eeditor literario
700 1 _aOliva, Stefano,
_eeditor literario
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-40236-9
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
988 _aSpringer_Medicine_2017
998 _b02/2018
_dz
_e-
_zSI
999 _c96613
_d96613
_x1